Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CBT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CBT and 80,000+ other tickers.
See exactly how CBT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CBT and 80,000+ other tickers.
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals. The company offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions. It also provides specialty carbons for use in inks, coatings, plastics, adhesives, toners, batteries, and displays; conductive additives and fumed alumina used in lead…
Cabot (CBT) reported earnings 30 days ago. What's next for the stock?
CBT is riding battery-materials growth, circular products and capacity expansion, even as weaker pricing and rising costs pressure profitability.
BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced that it priced a public offering of $350 million of 4.950% senior unsecured notes due 2029. The notes are being sold to the public at a price of 99.993% of the face amount thereof.
Cabot's Q3 fiscal 2026 earnings beat estimates as Performance Chemicals gains offset Reinforcement Materials margin pressure.
Cabot NYSE: CBT reported third-quarter fiscal 2026 adjusted earnings per share of $1.67, up 4% sequentially, as strength in its Performance Chemicals segment helped offset lower earnings in Reinforcement Materials.